ClinicalTrials.gg
Active, not recruitingNCT07852884INSPIRE-RCCUpdated Oct 1, 2026

First-Line Systemic Therapies in Advanced Renal Cell Carcinoma in Spain

An observational study in Renal Cell Carcinoma (RCC), sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-01.

Sponsored by Bristol-Myers Squibb · Observational

How we know · 6 judgments

Updated Oct 1, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
1,200
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb — 5 open to participants now, 8 under way, 2 of them phase 3. Carcinoma, Renal Cell · Bristol-Myers Squibb.

Started
2026
with 3 others
Observational
9 of 42
none open now
Registered
42nd of 42
by date

Among the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, this one is one of 4 that started in 2026, is one of 9 observational ones, and was the 42nd registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

5 of the 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Carcinoma, Renal Cell by Bristol-Myers Squibb, or all of them as a file.
02

Study summary

This retrospective observational study will use anonymized electronic medical records from the BIG-PAC® database to describe outcomes and treatment management for adults in Spain with advanced or metastatic renal cell carcinoma who start first-line systemic therapy.

03

Conditions studied

  • Renal Cell Carcinoma (RCC)

Keywords

  • Renal cell carcinoma (RCC)
  • advanced renal cell carcinoma (aRCC)
  • metastatic renal cell carcinoma (mRCC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adults (≥18 years) in Spain with a confirmed diagnosis of advanced or metastatic renal cell carcinoma who initiate first-line systemic therapies from January 1, 2019, to December 31, 2024.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years at the index date.
  • Documented diagnosis of advanced renal cell carcinoma (aRCC) identified through International Classification of Diseases (ICD) 9 codes recorded in medical history
  • Initiation of systemic therapies within the study selection period (January 1, 2019, to December 31, 2024).
  • A minimum of 12 months of follow-up data available after the index date, unless the participant dies earlier.
  • Availability of sufficient clinical data for evaluation of primary endpoints [overall survival (OS), progression-free survival (PFS), objective response rate (ORR), duration of response (DoR), time to response (TTR), safety).
  • Documented clinical follow-up at the treating center during first-line systemic therapies and at least one post-treatment initiation follow-up record.
  • Note: International RCC Database Consortium (IMDC) classification is not an inclusion criterion; IMDC intermediate/poor defines the primary analysis cohort

Exclusion criteria

Exclusion Criteria:

  • Insufficient clinical information in the electronic medical records (EMR) to evaluate the study outcomes (OS, PFS, ORR, safety).
  • Participation in an interventional clinical trial during treatment with systemic therapies that may affect clinical or safety outcomes.
  • Receipt of first line treatments outside routine clinical practice, such as compassionate use, expanded access, or off-label administration when relevant to the study objectives.
  • Diagnosis is inconsistent with advanced or RCC, including non-epithelial renal tumors or histology not aligned with the study population.
  • Age \<18 years at the time of first-line systemic therapies initiation.
  • If additional data-driven exclusions are identified during data validation, they may be described in the Statistical Analysis Plan (SAP) but will not be added as protocol-defined criteria.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
1,200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Intermediate- and poor-risk advanced or metastatic renal cell carcinoma

    Participants diagnosed with advanced or metastatic renal cell carcinoma who initiated a first-line systemic regimen during the study period and were classified as International Metastatic RCC Database Consortium intermediate- or poor-risk.

    Drug: First-line systemic regimens

Interventions

  • DrugFirst-line systemic regimens

    First-line systemic regimens for advanced or metastatic renal cell carcinoma include: nivolumab plus ipilimumab, axitinib plus avelumab, axitinib plus pembrolizumab, lenvatinib plus pembrolizumab, cabozantinib plus nivolumab, cabozantinib, tivozanib, sunitinib, and pazopanib

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., LenvatinibStudies of LenvatinibLenvatinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., IpilimumabStudies of IpilimumabIpilimumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., CabozantinibStudies of CabozantinibCabozantinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Overall survival from index date to death from any cause

    Time frame: Up to 7 years

Secondary outcomes

  1. Progression-free survival from index date to progression or death

    Time frame: Up to 7 years

  2. Objective response rate (ORR) based on documented complete or partial response

    Objective response rate is defined as the proportion of participants with documented partial response or complete response based on oncology or radiology electronic medical record entries.

    Time frame: Up to 7 years

  3. Duration of response (DoR) from first documented response to progression or death

    Time frame: Up to 7 years

  4. Time to response (TRR) from index date to first documented response

    Time frame: Up to 7 years

  5. Treatment-free survival (TFS) after discontinuation of first-line treatment

    Treatment-free survival is defined as the time from documented discontinuation of first-line treatment to the earliest of initiation of any subsequent systemic anti-cancer therapy or death.

    Time frame: Up to 7 years

  6. Outcome 6 Title Number of participants with adverse events

    Time frame: Up to 7 years

  7. Healthcare resource utilization during follow-up

    Healthcare resource utilization includes all-cause hospitalizations, emergency room visits, outpatient visits, diagnostic procedures including computed tomography, magnetic resonance imaging, and laboratory assessments, and systemic therapy administrations.

    Time frame: Up to 7 years

  8. Direct healthcare costs during follow-up

    Direct healthcare costs are estimated using a unit-cost method applied to medications and healthcare resource utilization. Cost categories include medication costs, hospital service costs, outpatient care costs, diagnostic procedure costs, supportive care costs, and total direct cost.

    Time frame: Up to 7 years

  9. Treatment duration from first-line therapy dose to discontinuation, switch, or end of follow-up

    Time frame: Up to 7 years

  10. Number of ipilimumab doses administered to participants receiving first-line nivolumab plus ipilimumab

    Time frame: Up to 7 years

  11. Number of participants that discontinue treatment

    Time frame: Up to 7 years

  12. Subsequent systemic therapy regimens prescribed after first-line treatment discontinuation

    Time frame: Up to 7 years

  13. Number of participants with prior adjuvant anti-programmed cell death protein 1 (PD-1) exposure

    Time frame: Up to 12 months prior to Index Date

07

Study locations

1 site
  • Local Institution - 0001
    Madrid, 28001, Spain
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2026 to primary completion in Sep 2026, 1 month.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2026
First posted
Oct 1, 2026
StartActual
Jul 15, 2026
Primary completionActual
Sep 1, 2026
CompletionEst.
Dec 1, 2026
Last update
Oct 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 1, 2026
Show all 1 update
  1. Oct 1, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07852884
Responsible party
Sponsor
First posted
Oct 1, 2026
Start date
Jul 15, 2026
Primary completion
Sep 1, 2026
Completion
Dec 1, 2026 (estimated)
Last update
Oct 1, 2026

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion